Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 10, 1990
Grant Date -
N/A
app pub date -
Feb 20, 1987
filing date -
Feb 20, 1987
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed is a screening assay for determining the amount of Superoxide Dismutase (SOD-1) in extra-cellular body fluids, for use in determining Trisomy 21 Down syndrome in a fetus. The assay can be done by any of a number of well known techniques including Radioimmunoassay, an Enzyme Linked Immunoassay, or a luminescence assay, single or tandem antibody type, carried out in solid or liquid phase. Polyclonal or monoclonal antibodies can be used. In the preferred embodiment, the assay is used to determine SOD-1 levels in amniotic fluid. A level above a threshold indicates a high probability of Trisomy 21 Down Syndrome for the fetus.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully